Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16428073 | 1.00 | BCHE (0.36) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251792 | 0.95 | BCHE (0.35) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251762 | 0.95 | BCHE (0.35) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251761 | 0.95 | BCHE (0.35) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251793 | 0.95 | BCHE (0.35) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15256239 | 0.82 | BCHE (0.39) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251978 | 0.82 | BCHE (0.39) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251788 | 0.82 | BCHE (0.39) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251789 | 0.82 | BCHE (0.39) | BCHEHSD17B3CNR2TACR1 | |
| SCHEMBL15251859 | 0.82 | SMN1; SMN2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9259491-B2 | Class of diazepine derivative chelating agents and complexes with paramagnetic metals thereof as MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2016-02-16 | — | — | US | disclosed |
| US-20150037261-A1 | New Class Of Diazepine Derivative Chelating Agents And Complexes With Paramagnetic Metals Thereof As MRI Contrast Agents | BRACCO IMAGING S.P.A. (IT) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037261-A1 | New Class Of Diazepine Derivative Chelating Agents And Complexes With Paramagnetic Metals Thereof As MRI Contrast Agents | BAZ2A, BAZ2B, BAZ1A | BCHE 2645/4885HSD17B3 4524/4885CNR2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.